The global non-opioid pain patches market is estimated to grow at a CAGR of nearly 4.5% during the forecast period. The rising incidences of neuropathic pain have led to the demand for non-opioid pain patches. Neuropathic pain condition is normally chronic, which is often caused by progressive, chronic, nerve disease, and can occur due to the injury or infection. Rising incidences of spinal cord injury and increasing prevalence of diabetes are some major causes of neuropathic pain. According to the National Spinal Cord Injury Statistical Center, as of 2019, in the US, the incidence of spinal cord injury is nearly 54 cases per one million people, or nearly 17,730 new spinal cord injury cases each year.
Browse the full report description Global Non-Opioid Pain Patches Market Size, Share & Trends Analysis Report, By Patch Type (Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, Others), By Distribution Channel (Hospitals, Online Pharmacies, and Drug Stores) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/non-opioid-pain-patches-market
As of 2019, in the US, the estimated number of people with spinal cord injury is nearly 291,000. An estimated 78% of new incidences have witnessed among males. People suffering from spinal cord injury may suffer from several forms of pain which occurs in various areas of the body, such as neuropathic pain, musculoskeletal pain, and visceral pain. Spinal cord injury may result in damage to any part of the spine or nerve which causes abnormal communication between the nerves and this condition results in neuropathic pain. This contributes to the increasing demand for pain management techniques to reduce the amount of pain.
Lidocaine patches are used to provide relief from pain occurs due to post-herpetic neuralgia. It works by stopping nerves from transmitting pain signals. Rising prevalence of diabetic patients is further leading the demand for neuropathic pain management. Nerve damage is more common in the diabetic population, which results in the increasing prevalence of diabetic neuropathy. Owing to the rising prevalence of diabetic neuropathy, the non-opioid patch manufacturers are launching new products for potential relief from pain.
For instance, in December 2019, Averitas Pharma, Inc. declared the supplemental New Drug Application (sNDA) for QUTENZA (capsaicin 8% patch) to treat neuropathic pain associated with diabetic peripheral neuropathy. This is a major step forward for the company towards the goal of getting QUTENZA FDA approved for diabetic peripheral neuropathy. There are millions of patients suffering from painful diabetic peripheral neuropathy and looking for effective pain relief. These novel pipeline products are expected to offer an opportunity for the growth of the global non-opioid pain patches market.
Global Non-Opioid Pain Patches Market- Segmentation
By Patch Type
By Distribution Channel
Global Non-Opioid Pain Patches Market– Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/non-opioid-pain-patches-market